| Ytd | -97.61% | |
| 1y | -98.98% |
| Open | 0.82 | Prev Close | 0.83 | Low | 0.77 | High | 0.83 | Mkt Cap | 51.81K |
| Vol | 70.33K | Avg Vol | 97.16K | EPS | -43.74 | P/E | -0.02 | Forward P/E | -0.37 |
| Beta | -0.06 | Short Ratio | 1.12 | Inst. Own | 1.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 2.11 | 200-d Avg | 21.83 | 1yr Est | 6.00 |
JAGX News
As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upo
As announced , Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 up
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to prov
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide
Gainers NovoCure (NASDAQ:NVCR) shares moved upwards by 27.7% to $19.88 during Thursday's regula
As announced, Napo has previously provided crofelemer powder for oral solution to treat select infan
Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adju
Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.6% to $0.18 during Thursday's
Company remains sharply focused on its ongoing global development program for crofelemer for rare IF
Major M&A deals this week include: Adobe buys Topaz Labs, Rise Baking Company purchases Jimmy
Company remains sharply focused on its ongoing global development program for crofelemer for rare in
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the company has completed
Jaguar's recently completed pivotal effectiveness study of crofelemer for the treatment of CID in do
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that i
Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Scienc
Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Sciences Virtu
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the results of a preclinic
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss ma
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss ma
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, presid
Click here to register for event To access the replay of the June 10, 2026 presentation by Lisa Cont
Lisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging
Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guida
JAGX's securities continue to be listed and traded on Nasdaq SAN FRANCISCO, CA / ACCESS Newswire / M
Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(13.60) per share which missed the analyst
Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs.
Click here to register for Jaguar's May 26 webcast; Click here to register for May 28 virtual presen
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) announced tha
First MVID patient enters the active treatment only extension phase after completion of randomized d
SAN FRANCISCO, CA / ACCESS Newswire / May 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or t
Jaguar Health Inc (NASDAQ:JAGX) shares are climbing Wednesday morning. The momentum follows the comp
Jaguar Health Inc. shares are climbing Wednesday after preliminary FDA talks on Breakthrough Therapy
Preliminary discussion with the Division of Gastroenterology at U.S. Food and Drug Administration (F
Pediatric patients with Intestinal Failure (IF) due to MVID, an ultrarare congenital disorder with l
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced topline results from the completion of it
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that o
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announce
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it plans to use AI platforms to enhance its d
Crofelemer, under the name Canalevia-CA1, is currently conditionally approved for the sole indicatio
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that t
As announced, Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 up
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that i